QDEL logo

QuidelOrtho Corp Com (QDEL)

$9.87

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on QDEL

Market cap

$677206244

EPS

-5.44

P/E ratio

--

Price to sales

0.34

Dividend yield

--

Beta

0.77173

Price on QDEL

Previous close

$10.21

Today's open

$10.15

Day's range

$9.82 - $10.64

52 week range

$9.82 - $35.58

Profile about QDEL

CEO

Brian J. Blaser

Employees

6500

Headquarters

San Diego, CA

Exchange

Nasdaq Global Select

Shares outstanding

68612588

Issue type

Common Stock

QDEL industries and sectors

Healthcare

Medical Equipment & Supplies

News on QDEL

QuidelOrtho (QDEL) Securities Investigation Notice - Levi & Korsinsky

QuidelOrtho shares fell roughly 14% after third-quarter 2026 results showed China revenue down 45% and respiratory revenue down 39%. Levi & Korsinsky is investigating on behalf of investors who lost money.

news source

PRNewsWire • Nov 16, 2026

news preview

Levi & Korsinsky Notifies Investors of Pending Investigation Into Securities Claims Involving QuidelOrtho (QDEL)

Point-of-Care revenue down 27% and total sales down roughly 12% year over year: QuidelOrtho's third-quarter 2026 revenue miss against Wall Street consensus sent shares down approximately 14% Point-of-Care revenue down 27% and total sales down roughly 12% year over year: QuidelOrtho's third-quarter 2026 revenue miss against Wall Street consensus sent shares down approximately 14%

news source

GlobeNewsWire • Nov 12, 2026

news preview

Did QuidelOrtho Corporation Insiders Breach their Fiduciary Duties to Shareholders?

Shareholders are encouraged to contact the firm to discuss their rights and options at no cost or obligation. We would handle any matter on a contingent fee basis, whereby you would not be responsible for out-of-pocket payment of our legal fees or expenses.

news source

PRNewsWire • Nov 12, 2026

news preview

QuidelOrtho Investigation Initiated: Kahn Swick & Foti, LLC Investigates the Officers and Directors of QuidelOrtho Corporation - QDEL

NEW ORLEANS--(BUSINESS WIRE)--Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (“KSF”), announces that KSF has commenced an investigation into QuidelOrtho Corporation (“QuidelOrtho” or the “Company”) (NasdaqGS: QDEL). According to a securities class action filed against the Company, internal reports and accounts from former employees described serious and unresolved problems with the Company's flagship test, the Savanna Re.

news source

Business Wire • Nov 11, 2026

news preview

QDEL SHAREHOLDER INVESTIGATION: SueWallSt Notifies Investors of Potential Securities Claims Involving QuidelOrtho

QuidelOrtho's May 2026 quarterly report said China's volume-based procurement program would not likely have a material impact on total annualized revenue. Third-quarter 2026 results showed China revenue down 45%, and QDEL shares fell roughly 14%.

news source

PRNewsWire • Nov 10, 2026

news preview

QuidelOrtho Investigation Notice: Levi & Korsinsky Notifies Investors of Pending Investigation Into QuidelOrtho (QDEL)

QuidelOrtho narrowed its full-year revenue outlook and announced a restructuring program with its third-quarter 2026 results, and shares fell roughly 14%. QDEL shareholders who lost money have rights, and Levi & Korsinsky is investigating potential securities law violations.

news source

PRNewsWire • Nov 9, 2026

news preview

QuidelOrtho Corporation (QDEL) Q3 2026 Earnings Call Transcript

QuidelOrtho Corporation ( QDEL ) Q3 2026 Earnings Call November 3, 2026 5:00 PM EST Company Participants Sanjeev Sharma Brian Blaser - President, CEO & Director Micah Young - Chief Financial Officer & Principal Financial Officer Conference Call Participants William Bonello - Craig-Hallum Capital Group LLC, Research Division Tycho Peterson - Jefferies LLC, Research Division Jack Meehan - Operon Research, LLC Casey Woodring - JPMorgan Chase & Co, Research Division Presentation Operator Welcome to the QuidelOrtho Third Quarter 2026 Financial Results Conference Call and webcast. [Operator Instructions] Please note, this conference call is being recorded.

news source

Seeking Alpha • Nov 4, 2026

news preview

What QuidelOrtho (QDEL) Said on Its Q3 Earnings Call

QuidelOrtho NASDAQ: QDEL reported third-quarter revenue of $619 million, down 12% year over year on a constant-currency basis, as China pricing changes and softer respiratory testing demand continued to weigh on results. The company said revenue rose 3% excluding China, respiratory testing and the prior-year contribution from its U.S. Donor Screening business, which it is winding down.

news source

MarketBeat • Nov 4, 2026

news preview

QuidelOrtho Reports Third Quarter 2026 Financial Results

― Growth in Labs and Immunohematology Outside of China Highlights Underlying Business Strength ― ― New Cost Transformation and Enterprise Restructuring Program Expected to Deliver Over $80 Million in Annual Savings in 2027 ― ― Updated Full-Year 2026 Financial Guidance Narrowing Prior Ranges ― SAN DIEGO, Nov. 3, 2026 /PRNewswire/ -- QuidelOrtho Corporation (Nasdaq: QDEL) (the "Company" or "QuidelOrtho"), a leading global provider of diagnostic solutions, today announced financial results for the third quarter ended September 27, 2026. Key Third Quarter 2026 Results: (all comparisons are to the prior year period) Total revenue was $619 million, a decrease of 12% both as reported and in constant currency.

news source

PRNewsWire • Nov 3, 2026

news preview

QuidelOrtho (QDEL) Beats Q3 Earnings and Revenue Estimates

QuidelOrtho (QDEL) came out with quarterly earnings of $0.31 per share, beating the Zacks Consensus Estimate of $0.18 per share. This compares to earnings of $0.8 per share a year ago.

news source

Zacks Investment Research • Nov 3, 2026

news preview

¹ Disclosures

Get started with M1

Invest in QuidelOrtho Corp Com

Open an M1 investment account to buy and sell QuidelOrtho Corp Com commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in QDEL on M1